Full Papers
Long-term organ damage accrual and late mortality in systemic sclerosis
M.G. Lazzaroni1, L. Moschetti2, M. Breda3, F. Franceschini4, P. Airò5
- Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, and Department of Clinical and Experimental Sciences, University of Brescia, Italy.
- Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, and Department of Clinical and Experimental Sciences, University of Brescia, Italy.
- Department of Clinical and Experimental Sciences, University of Brescia, Italy.
- Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, and Department of Clinical and Experimental Sciences, University of Brescia, Italy.
- Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy. airopaolo@gmail.com
CER16917
2024 Vol.42, N°8
PI 1541, PF 1548
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 37933549 [PubMed]
Received: 15/06/2023
Accepted : 01/09/2023
In Press: 27/10/2023
Published: 13/08/2024
Abstract
OBJECTIVES:
Progressive organ damage accrual in patients with systemic sclerosis (SSc) can be measured using the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI). We aimed to evaluate the long-term evolution of organ damage accrual in SSc patients with at least 10 years of follow-up, identifying clinical and laboratory features associated with moderate and severe damage, and the association of SCTC-DI with “late mortality” (death >10 years after diagnosis).
METHODS:
In this single-centre retrospective study, patients with SSc were included when fulfilling the following characteristics: 1) a baseline visit corresponding to the time of diagnosis; 2) a minimum of 10 years of follow-up after diagnosis; 3) available follow-up visits at predefined timepoints.
RESULTS:
In 253 patients included in the study, SCTC-DI progressively increased from the baseline to 10 years after diagnosis, with 34% of patients showing moderate or severe damage at this time point. During the follow-up, the SCTC-DI score was higher, and had a higher annual rise, in dcSSc patients than in lcSSc and in ACA-negative patients than in ACA+. Multivariable analyses identified dcSSc, lack of ACA, and the SCTC-DI scores at previous timepoints as independent variables associated with moderate or severe damage. In patients with “late mortality”, as compared to surviving patients, the SCTC-DI score was demonstrated to be significantly higher at the baseline and at every timepoint, with a higher annual rise.
CONCLUSIONS:
Factors associated with damage accrual in SSc patients with long-term follow-up were identified. Higher SCTC-DI and higher SCTC-DI annual rise were associated with late mortality in SSc.
